R&D Pipeline

Guided by innovation and internationalization, Fosun Pharma increases its investment in R&D and the introduction of scientific research personnel, enriches its innovative product pipelines, improves its R&D and clinical trial capacities for new drugs, and speeds up the R&D and transformation of innovative technologies and products through diverse and multi-level cooperation models, such as independent R&D, co-development, in-licensing, and in-depth incubation.

Main pipelines

Data as of the end of 2022, Fosun Pharma had more than 260 pipelines under development, including innovative drugs, biosimilars, generic drugs and those for consistency evaluation.

  • 6
    self-developed innovator drugs (indications)
  • 4
    license-in innovator drugs (indications)
  • 27
    generic drugs (indications) of Fosun Pharma were approved for marketing in Chinese mainland/Hong Kong, China/United States
  • 7
    innovator drugs (indications)
  • 30
    generic drugs (indications) were applied for marketing in the Chinese mainland (NDA)
  • 22
    innovator drugs (indications) were approved for clinical trials (IND) in the Chinese mainland.